Business

Bioventus Announces Chief Financial Officer Transition Plan

DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active

articleBioventus Inc.November 15, 20214/company/bioventus-inc/news/bioventus-announces-chief-financial-officer-transition-plan
Bioventus Announces Chief Financial Officer Transition Plan

About this update from Bioventus Inc.

[{"type":"text","content":"DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (\"Bioventus\" or \"the Company\"), a global leader in innovations for active healing, today announced that Greg Anglum is transitioning from his role as Senior Vice President and Chief Financial Officer (CFO) to pursue other career opportunities. To ensure a smooth transition, Mr. Anglum will remain in his current role until a successor is named. “I want to thank Greg for his dedication to Bioventus over the past five years,” commented Ken Reali, Bioventus’ Chief Executive Officer. “I am grateful for his contributions through our initial public offering and our recent acquisitions of Bioness and Misonix. Greg has instilled the appropriate financial controls as we have made the transition to a public entity, and his efforts to strengthen our balance sheet have positioned us well to continue to invest in an innovative, rapidly growing active healing portfolio. We are working diligently to identify a CFO who brings robust experience leading a rapidly expanding organization and can work with me and my executive team to help take Bioventus to the next level of growth by enhancing the results-driven foundation and culture that we have built.” Mr. Anglum said, “As I begin the next chapter of my career, I am grateful for my experience working with Ken and the talented team at Bioventus. It has been a privilege to work alongside these dedicated individuals to bring innovative active healing solutions to market and improve the lives of countless patients.” Bioventus has been actively working with Spencer Stuart to identify a successor to Mr. Anglum. Mr. Anglum’s departure is unrelated to Bioventus’ business performance, financial reporting, or controls, and the Company is reaffirming its previously issued 2021 financial guidance. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.c...

More updates from Bioventus Inc.